Matches in SemOpenAlex for { <https://semopenalex.org/authorship/W2324153461A5023809431> ?p ?o ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- W2324153461A5023809431 type Authorship @default.
- W2324153461A5023809431 hasAuthor A5023809431 @default.
- W2324153461A5023809431 hasOrganization I1174212 @default.
- W2324153461A5023809431 hasOrganization I1336910626 @default.
- W2324153461A5023809431 hasOrganization I185261750 @default.
- W2324153461A5023809431 hasOrganization I2801317318 @default.
- W2324153461A5023809431 hasOrganization I4210086752 @default.
- W2324153461A5023809431 hasOrganization I4210141030 @default.
- W2324153461A5023809431 hasOrganization I49886154 @default.
- W2324153461A5023809431 isCorresponding "false" @default.
- W2324153461A5023809431 position "0" @default.
- W2324153461A5023809431 rawAffiliation "1Physiology and Experimental Medicine Program of the Research Institute of The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.; 2Departments of Anesthesiology and Critical Care Medicine and Respiratory Therapy, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA.; 3Department of Respiratory Therapy, Rush University, Chicago, IL.; Dr. Newth received funding from Philips Healthcare and disclosed off-label product use (epinephrine is frequently used for treatment of subglottic edema. Vapourization as a method of drug delivery for epinephrine has not previously been investigated). He disclosed that Vapotherm Inc. supported the study, but made no contribution to the analysis of the data or writing of this paper. Dr. Coates’s laboratory received funds to conduct the study from Vapotherm Inc. Dr. Leung disclosed off label product use (The drug itself is commonly used. Only the delivery device is still investigational). Dr. Hotz disclosed off-label product use (The authors discuss the use of Vapotherm to deliver a drug, clinically. Both Vapotherm and epinephrine are approved, but it is an off label system for delivering this drug). Dr. O'Brien disclosed off-label product use (Drug delivery in vapor form of epinephrine with high flow nasal cannula system). Dr. Fink disclosed work as a consultant to the Biomed industry (Clients include Ansun, Aridis, Bayer, WHO and others) and he received funding from Aerogen Ltd (as chief clinical officer; For information regarding this article, E-mail: [email protected]; Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/pccmjournal).; Supported, in part, by Vapotherm, but it made no contribution to the analysis of the data or to the writing of this article.; not related to this work), Dance Biopharm (He is Senior Fellow for Aerosol Device Development. Consultant not related to this paper), and Quark Pharma (Consultant). Dr. Coates disclosed other support (The limited amount of industry support was more than 5 years ago and once the initial analytical work was completed, there has been no industry support since) and disclosed off-label product use (This is an in vitro study with the potential use of off label products suggested for a future clinical study. There is no in vivo aspect of this study). His institution received funding from Vapotherm (To support the analytical work for the project. The project was investigator initiated and driven with some industry help but no scientific input from industry)." @default.